Further studies are also required to support the value of including GR expression in the algorithm of breast cancer testing, to test whether ER+ GR+ tumors have better prognosis and to test whether ER− GR+ tumors are more likely to develop chemoresistance and hence might benefit from anti-GR therapy. The gene discussed is NR3C1; the disease is breast carcinoma.